НовостиBenzingaUBS Maintains Buy on Rapport Therapeutics, Lowers Price Target to $64 UBS Maintains Buy on Rapport Therapeutics, Lowers Price Target to $64 Benzinga 2026.11.06 01:15 (GMT+0) Открыть на Benzinga Другие новости